Effectiveness of dolutegravir‐based regimens as either first‐line or switch antiretroviral therapy: data from the Icona cohort

Concerns about dolutegravir (DTG) tolerability in the real‐life setting have recently arisen. We aimed to estimate the risk of treatment discontinuation and virological failure of DTG‐based regimens from a large cohort of HIV‐infected individuals.

[1]  R. Shapiro,et al.  Neural-Tube Defects with Dolutegravir Treatment from the Time of Conception. , 2018, The New England journal of medicine.

[2]  P. Drain,et al.  Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: uncertainties and opportunities for implementation and research. , 2018, The lancet. HIV.

[3]  C. Fichtenbaum,et al.  Dolutegravir Plus Lamivudine Maintains Human Immunodeficiency Virus-1 Suppression Through Week 48 in a Pilot Randomized Trial , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  A. De Luca,et al.  Efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multicentre cohort of patients with suppressed HIV‐1 replication , 2018, HIV medicine.

[5]  C. Hung,et al.  Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies , 2018, The Lancet.

[6]  T. F. Rinke de Wit,et al.  Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling study , 2017, The lancet. HIV.

[7]  A. S. Team,et al.  Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study , 2017 .

[8]  Eleni-Rosalina Andrinopoulou,et al.  Dolutegravir as maintenance monotherapy for HIV (DOMONO): a phase 2, randomised non-inferiority trial. , 2017, The lancet. HIV.

[9]  H. Günthard,et al.  Adverse events of raltegravir and dolutegravir , 2017, AIDS.

[10]  J. Gatell,et al.  Tolerability of integrase inhibitors in a real-life setting , 2017, The Journal of antimicrobial chemotherapy.

[11]  A. Stein,et al.  Neuropsychiatric adverse effects on dolutegravir: an emerging concern in Europe. , 2017, AIDS.

[12]  N. Ford,et al.  When could new antiretrovirals be recommended for national treatment programmes in low-income and middle-income countries: results of a WHO Think Tank , 2017, Current opinion in HIV and AIDS.

[13]  J. Lake,et al.  Dolutegravir/Abacavir/Lamivudine versus Current ART in Virally Suppressed Patients (STRIIVING): A 48-Week, Randomized, Non-Inferiority, Open-Label, Phase IIIb Study , 2017, Antiviral therapy.

[14]  D. Cattaneo,et al.  Intolerance of dolutegravir-containing combination antiretroviral therapy: not just a pharmacokinetic drug interaction. , 2017, AIDS.

[15]  C. Mussini,et al.  Lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients , 2017, BMC Infectious Diseases.

[16]  A. Winston,et al.  Psychiatric Symptoms in Patients Receiving Dolutegravir , 2017, Journal of acquired immune deficiency syndromes.

[17]  P. Vitiello,et al.  Discontinuation of treatment and adverse events in an Italian cohort of patients on dolutegravir. , 2017, AIDS.

[18]  H. Stellbrink,et al.  Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients , 2017, HIV medicine.

[19]  K. Brinkman,et al.  Intolerance of dolutegravir-containing combination antiretroviral therapy regimens in real-life clinical practice , 2016, AIDS.

[20]  K. Brinkman,et al.  Intolerance of dolutegravir containing cART regimens in real life clinical practice. , 2016, AIDS.

[21]  B. Clotet,et al.  Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study , 2014, The Lancet.

[22]  R. Haubrich,et al.  Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study , 2014, The Journal of infectious diseases.

[23]  S. Walmsley,et al.  Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. , 2013, The New England journal of medicine.

[24]  P. Cahn,et al.  Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study , 2013, The Lancet.

[25]  Clare Brennan,et al.  Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study , 2013, The Lancet.

[26]  M. Moroni,et al.  Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients , 2000, AIDS.